{"url_path":"/sec/asbp/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-023802-index.html","accession_number":"0001493152-26-023802","cik":"0001847345","ticker":"ASBP","issuer_name":"Aspire Biopharma Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-023802-index.html","primary_entity_key":"0001847345","primary_entity_name":"Aspire Biopharma Holdings, Inc."},"word_count":1270,"has_tables":true,"body_markdown":"false\nQ1\n--12-31\n0001847345\n\n0001847345\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nASBP:CommonStockParValue0.0001PerShareMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nASBP:WarrantsEachExercisableForOneShareOfCommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\n2026-05-13\n\n0001847345\n\n2026-03-31\n\n0001847345\n\n2025-12-31\n\n0001847345\n\nASBP:AffiliatesMember\n\n2026-03-31\n\n0001847345\n\nASBP:AffiliatesMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:RelatedPartyMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:RelatedPartyMember\n\n2025-12-31\n\n0001847345\n\nASBP:SeriesAConvertiblePreferredStockMember\n\n2026-03-31\n\n0001847345\n\nASBP:SeriesAConvertiblePreferredStockMember\n\n2025-12-31\n\n0001847345\n\n2025-01-01\n2025-03-31\n\n0001847345\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:PreferredStockMember\nASBP:SeriesAConvertiblePreferredStockMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001847345\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001847345\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001847345\n\n2024-12-31\n\n0001847345\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nus-gaap:PreferredStockMember\nASBP:SeriesAConvertiblePreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001847345\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001847345\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001847345\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:PreferredStockMember\nASBP:SeriesAConvertiblePreferredStockMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001847345\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001847345\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001847345\n\n2025-03-31\n\n0001847345\n\n2025-02-28\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2025-02-01\n2025-02-28\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2025-02-28\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2026-02-01\n2026-02-28\n\n0001847345\n\nus-gaap:CommonStockMember\nASBP:PurchaseAgreementMember\n\n2025-11-01\n2025-11-30\n\n0001847345\n\nus-gaap:CommonStockMember\nASBP:PurchaseAgreementMember\n\n2026-04-01\n2026-04-30\n\n0001847345\n\n2026-01-16\n2026-01-16\n\n0001847345\n\nus-gaap:SubsequentEventMember\n\n2026-05-11\n2026-05-11\n\n0001847345\n\nus-gaap:CommonStockMember\n\n2025-02-17\n\n0001847345\n\n2025-01-01\n2025-12-31\n\n0001847345\n\nus-gaap:IPOMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:PrivatePlacementMember\n\n2026-03-31\n\n0001847345\n\n2025-02-17\n2025-02-17\n\n0001847345\n\nus-gaap:ParentMember\nASBP:CommonStockIssuedToExistingAspireBiopharmaIncShareholdersMember\n\n2025-02-17\n2025-02-17\n\n0001847345\n\nASBP:ConversionRatioMember\nASBP:CommonStockIssuedToExistingAspireBiopharmaIncShareholdersMember\n\n2025-02-17\n2025-02-17\n\n0001847345\n\nsrt:ParentCompanyMember\nASBP:CommonStockObligationSharesIssuedMember\n\n2025-02-17\n2025-02-17\n\n0001847345\n\nASBP:ConversionRatioMember\nASBP:CommonStockObligationSharesIssuedMember\n\n2025-02-17\n2025-02-17\n\n0001847345\n\nus-gaap:ParentMember\n\n2025-02-17\n2025-02-17\n\n0001847345\n\nASBP:ConversionRatioMember\n\n2025-02-17\n2025-02-17\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:SponsorAndSsvkAssociatesLlcMember\n\n2025-02-17\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:SponsorAndSsvkAssociatesLlcMember\n\n2026-03-31\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:SponsorAndSsvkAssociatesLlcMember\n\n2025-12-31\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:ApogeePharmaMember\n\n2025-02-17\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:ApogeePharmaMember\n\n2026-03-31\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:ApogeePharmaMember\n\n2025-12-31\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:JinalShethMember\n\n2025-02-17\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:JinalShethMember\n\n2026-03-31\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:JinalShethMember\n\n2025-12-31\n\n0001847345\n\nASBP:SecondLoanAndTransferAgreementtMember\nASBP:ApogeePharmaTwoMember\n\n2025-02-17\n\n0001847345\n\nASBP:SecondLoanAndTransferAgreementtMember\nASBP:ApogeePharmaTwoMember\n\n2026-03-31\n\n0001847345\n\nASBP:SecondLoanAndTransferAgreementtMember\nASBP:ApogeePharmaTwoMember\n\n2025-12-31\n\n0001847345\n\nASBP:FirstSubscriptionAgreementMember\n\n2024-03-05\n2024-03-05\n\n0001847345\n\nASBP:SecondSubscriptionAgreementsMember\n\n2024-05-09\n2024-05-09\n\n0001847345\n\nASBP:FirstSubscriptionAgreementMember\n\n2025-02-17\n\n0001847345\n\nASBP:FirstAndSecondSubscriptionAgreementMember\n\n2026-03-31\n\n0001847345\n\nASBP:FirstAndSecondSubscriptionAgreementMember\n\n2025-12-31\n\n0001847345\n\n2025-02-17\n\n0001847345\n\nASBP:ModifiedPromissoryNoteFeeAgreementMember\n\n2024-10-02\n\n0001847345\n\n2024-09-27\n2024-09-27\n\n0001847345\n\n2024-09-27\n\n0001847345\n\nASBP:SeptemberTwentySevenTwoThousandTwentyFourMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nASBP:SeptemberTwentySevenTwoThousandTwentyFourMember\n\n2025-01-01\n2025-03-31\n\n0001847345\n\n2024-12-30\n2024-12-30\n\n0001847345\n\n2024-12-31\n2024-12-31\n\n0001847345\n\nASBP:DecemberThirtyFirstTwoThousandTwentyFourMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nASBP:DecemberThirtyFirstTwoThousandTwentyFourMember\n\n2025-01-01\n2025-03-31\n\n0001847345\n\nus-gaap:RelatedPartyMember\nASBP:SeptemberTwentySevenTwoThousandTwentyFourMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:RelatedPartyMember\nASBP:SeptemberTwentySevenTwoThousandTwentyFourMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:RelatedPartyMember\nASBP:DecemberThirtyFirstTwoThousandTwentyFourMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:RelatedPartyMember\nASBP:DecemberThirtyFirstTwoThousandTwentyFourMember\n\n2025-12-31\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\nASBP:CobraAlternativeCapitalStrategiesLLCMember\n\n2025-02-17\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\nASBP:CobraAlternativeCapitalStrategiesLLCMember\n\n2025-02-17\n2025-02-17\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2025-08-01\n2025-08-31\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2025-09-01\n2025-09-30\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2025-01-01\n2025-03-31\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2026-01-01\n2026-01-31\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2026-03-31\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2025-12-31\n\n0001847345\n\nASBP:AugustSecuritiesPurchaseAgreementMember\nASBP:AugustTwentyTwentyFiveNotesMember\n\n2025-08-19\n\n0001847345\n\nASBP:AugustSecuritiesPurchaseAgreementMember\nASBP:AugustTwentyTwentyFiveNotesMember\n\n2025-08-19\n2025-08-19\n\n0001847345\n\nASBP:AugustSecuritiesPurchaseAgreementMember\nASBP:AugustTwentyTwentyFiveNotesMember\n\n2025-08-18\n\n0001847345\n\nASBP:AugustSecuritiesPurchaseAgreementMember\n\n2025-08-19\n\n0001847345\n\nASBP:AugustSecuritiesPurchaseAgreementMember\nASBP:FirstTrancheMember\n\n2025-08-19\n\n0001847345\n\nASBP:AugustSecuritiesPurchaseAgreementMember\nASBP:SecondTrancheMember\n\n2025-09-22\n\n0001847345\n\nASBP:AugustSecuritiesPurchaseAgreementMember\nASBP:ThirdTrancheMember\n\n2025-09-30\n\n0001847345\n\nASBP:AugustSecuritiesPurchaseAgreementMember\nASBP:AugustTwentyTwentyFiveNotesMember\n\n2025-01-01\n2025-12-31\n\n0001847345\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-01-31\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\nASBP:DebenturesMember\n\n2026-01-26\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\nASBP:DebenturesMember\n\n2026-01-26\n2026-01-26\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\nASBP:DebenturesMember\n\n2026-03-31\n\n0001847345\n\nASBP:NutraceuticalProductsMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\ncountry:US\n\n2026-01-01\n2026-03-31\n\n0001847345\n\ncountry:CA\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nus-gaap:NonUsMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nus-gaap:WarrantMember\n\n2025-05-13\n\n0001847345\n\nASBP:PrivatePlacementWarrantsMember\n\n2025-05-13\n\n0001847345\n\nASBP:SecondELOCAgreementMember\nASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember\n\n2025-11-11\n2025-11-11\n\n0001847345\n\nASBP:SecondELOCAgreementMember\nASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember\n\n2025-11-11\n2025-12-31\n\n0001847345\n\nASBP:SecondELOCAgreementMember\nASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember\n\n2026-01-01\n2026-01-31\n\n0001847345\n\nASBP:SecondELOCAgreementMember\nASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nASBP:SecondELOCAgreementMember\nASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember\n\n2025-01-01\n2025-03-31\n\n0001847345\n\nASBP:SecondELOCAgreementMember\n\n2026-03-31\n\n0001847345\n\nASBP:SecondELOCAgreementMember\n\n2025-12-31\n\n0001847345\n\nASBP:InstaprinPharmaceuticalsIncMember\n\n2022-03-28\n\n0001847345\n\nASBP:InstaprinPharmaceuticalsIncMember\n\n2022-03-28\n2022-03-28\n\n0001847345\n\nus-gaap:SeriesAPreferredStockMember\n\n2026-02-02\n\n0001847345\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesAPreferredStockMember\n\n2026-02-02\n\n0001847345\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesAPreferredStockMember\n\n2026-02-02\n2026-02-02\n\n0001847345\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesAPreferredStockMember\n\n2026-02-06\n2026-02-06\n\n0001847345\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesAPreferredStockMember\nus-gaap:SubsequentEventMember\n\n2026-04-13\n\n0001847345\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesAPreferredStockMember\nus-gaap:SubsequentEventMember\n\n2026-04-15\n2026-04-15\n\n0001847345\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesAPreferredStockMember\nus-gaap:SubsequentEventMember\n\n2026-04-15\n\n0001847345\n\nus-gaap:SeriesAPreferredStockMember\n\n2026-02-02\n2026-02-02\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\nus-gaap:SeriesAPreferredStockMember\n\n2026-02-06\n2026-02-06\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\nus-gaap:SeriesAPreferredStockMember\n\n2026-02-06\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2026-02-06\n\n0001847345\n\nASBP:SecuritiesPurchaseAgreementMember\n\n2026-02-06\n2026-02-06\n\n0001847345\n\nASBP:SeriesAConvertiblePreferredStockMember\nus-gaap:SubsequentEventMember\n\n2026-04-13\n\n0001847345\n\nus-gaap:SubsequentEventMember\nASBP:SecuritiesPurchaseAgreementMember\nus-gaap:SeriesAPreferredStockMember\nASBP:SecondClosingMember\n\n2026-04-15\n2026-04-15\n\n0001847345\n\nus-gaap:SubsequentEventMember\nASBP:SecuritiesPurchaseAgreementMember\nus-gaap:SeriesAPreferredStockMember\n\n2026-04-15\n2026-04-15\n\n0001847345\n\nus-gaap:CommonClassAMember\nASBP:PublicWarrantsMember\n\n2026-03-31\n\n0001847345\n\nASBP:PrivatePlacementWarrantsMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:CommonClassAMember\nASBP:PrivatePlacementWarrantsMember\n\n2026-03-31\n\n0001847345\n\nASBP:PublicWarrantsMember\n\n2026-03-31\n\n0001847345\n\nASBP:PublicWarrantsMember\n\n2025-12-31\n\n0001847345\n\nASBP:PrivatePlacementWarrantsMember\n\n2025-12-31\n\n0001847345\n\nASBP:PublicWarrantsMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nASBP:CorporateAdvisoryAgreementMember\n\n2024-02-29\n2024-02-29\n\n0001847345\n\nASBP:CorporateAdvisoryAgreementMember\n\n2025-01-03\n2025-01-03\n\n0001847345\n\nASBP:CorporateAdvisoryAgreementMember\n\n2025-02-01\n2025-02-28\n\n0001847345\n\nASBP:CorporateAdvisoryAgreementMember\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nASBP:CorporateAdvisoryAgreementMember\n\n2025-01-01\n2025-03-31\n\n0001847345\n\nASBP:AspireBiopharmaWarrantsMember\n\n2024-12-31\n\n0001847345\n\nASBP:AspireBiopharmaWarrantsMember\n\n2025-01-21\n\n0001847345\n\nASBP:AspireBiopharmaWarrantsMember\n\n2025-01-21\n2025-01-21\n\n0001847345\n\nASBP:AspireBiopharmaWarrantsMember\n\n2026-01-16\n2026-01-16\n\n0001847345\n\nASBP:SettlementAgreementMember\n\n2025-04-28\n2025-04-28\n\n0001847345\n\nASBP:ConvertibleNotesMember\n\n2025-01-01\n2025-12-31\n\n0001847345\n\nus-gaap:CommonStockMember\nASBP:ConvertibleNotesMember\n\n2026-01-01\n2026-01-31\n\n0001847345\n\nASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember\n\n2026-01-01\n2026-01-31\n\n0001847345\n\nus-gaap:CommonStockMember\nus-gaap:InvestorMember\nASBP:SharePurchaseAgreementMember\n\n2026-01-01\n2026-01-31\n\n0001847345\n\nASBP:ExchangeAgreementsMember\n\n2026-01-01\n2026-01-01\n\n0001847345\n\nASBP:ExchangeAgreementsMember\n\n2026-01-01\n2026-01-31\n\n0001847345\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:FairValueInputsLevel1Member\n\n2026-03-31\n\n0001847345\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:FairValueInputsLevel2Member\n\n2026-03-31\n\n0001847345\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:FairValueInputsLevel3Member\n\n2026-03-31\n\n0001847345\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:FairValueInputsLevel1Member\n\n2025-12-31\n\n0001847345\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:FairValueInputsLevel2Member\n\n2025-12-31\n\n0001847345\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:FairValueInputsLevel3Member\n\n2025-12-31\n\n0001847345\n\nus-gaap:ConvertibleNotesPayableMember\nus-gaap:MeasurementInputExpectedTermMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:ConvertibleNotesPayableMember\nus-gaap:MeasurementInputSharePriceMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:ConvertibleNotesPayableMember\nus-gaap:MeasurementInputRiskFreeInterestRateMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:FairValueInputsLevel3Member\n\n2025-12-31\n\n0001847345\n\nus-gaap:FairValueInputsLevel3Member\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nus-gaap:FairValueInputsLevel3Member\n\n2026-03-31\n\n0001847345\n\nus-gaap:MeasurementInputSharePriceMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:MeasurementInputSharePriceMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:MeasurementInputRiskFreeInterestRateMember\nsrt:MinimumMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:MeasurementInputRiskFreeInterestRateMember\nsrt:MaximumMember\n\n2026-03-31\n\n0001847345\n\nus-gaap:MeasurementInputRiskFreeInterestRateMember\nsrt:MinimumMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:MeasurementInputRiskFreeInterestRateMember\nsrt:MaximumMember\n\n2025-12-31\n\n0001847345\n\nASBP:MeasurementInputLikelihoodMember\nsrt:MinimumMember\n\n2026-03-31\n\n0001847345\n\nASBP:MeasurementInputLikelihoodMember\nsrt:MaximumMember\n\n2026-03-31\n\n0001847345\n\nASBP:MeasurementInputLikelihoodMember\nsrt:MinimumMember\n\n2025-12-31\n\n0001847345\n\nASBP:MeasurementInputLikelihoodMember\nsrt:MaximumMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember\nus-gaap:FairValueInputsLevel3Member\n\n2025-12-31\n\n0001847345\n\nus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember\nus-gaap:FairValueInputsLevel3Member\n\n2026-01-01\n2026-03-31\n\n0001847345\n\nus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember\nus-gaap:FairValueInputsLevel3Member\n\n2026-03-31\n\n0001847345\n\nus-gaap:MeasurementInputExpectedTermMember\nsrt:MinimumMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:MeasurementInputExpectedTermMember\nsrt:MaximumMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:MeasurementInputSharePriceMember\nsrt:MinimumMember\n\n2025-12-31\n\n0001847345\n\nus-gaap:MeasurementInputSharePriceMember\nsrt:MaximumMember\n\n2025-12-31\n\n0001847345\n\nASBP:SecondClosingMember\nus-gaap:SubsequentEventMember\n\n2026-04-15\n2026-04-15\n\n0001847345\n\nus-gaap:PreferredStockMember\nus-gaap:SubsequentEventMember\n\n2026-05-15\n2026-05-15\n\n0001847345\n\nus-gaap:CommonStockMember\nus-gaap:SubsequentEventMember\n\n2026-05-15\n2026-05-15\n\n0001847345\n\nASBP:DriverControlsSystemsBusinessUnitMember\nus-gaap:SubsequentEventMember\n\n2026-05-15\n\n0001847345\n\nASBP:DriverControlsSystemsBusinessUnitMember\nus-gaap:SubsequentEventMember\n\n2026-04-15\n2026-04-15\n\n0001847345\n\nASBP:AspireCreditFacilityMember\nus-gaap:SubsequentEventMember\n\n2026-04-15\n2026-04-15\n\n0001847345\n\nASBP:AspireCreditFacilityMember\nASBP:DriverControlsSystemsBusinessUnitMember\nus-gaap:SubsequentEventMember\n\n2026-04-15\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:SSVKAssociatesLLCMember\nus-gaap:SubsequentEventMember\n\n2026-04-14\n2026-04-14\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:JinalShethMember\nus-gaap:SubsequentEventMember\n\n2026-04-15\n2026-04-15\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:SSVKAssociatesLLCMember\nus-gaap:SubsequentEventMember\n\n2026-04-14\n\n0001847345\n\nASBP:LoanAndTransferAgreementMember\nASBP:JinalShethMember\nus-gaap:SubsequentEventMember\n\n2026-04-15\n\n0001847345\n\nus-gaap:SubsequentEventMember\n\n2026-04-30\n2026-04-30\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nASBP:Integer\n\nxbrli:pure\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n(Mark\nOne)\n\n \n\n**☒\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe quarterly period ended March 31. 2026**\n\n \n\n**☐\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe transition period from to**\n\n \n\n**Commission\nFile No. 001-41293**\n\n \n\n**ASPIRE\nBIOPHARMA HOLDINGS, INC.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n**Delaware**\n \n**33-3467744**\n\n(State\nor other jurisdiction of\n\nincorporation\nor organization)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNo.)\n\n \n\n**23150\nFashion Drive, Suite 232**\n\n**Estero,\nFlorida 33928**\n\n(Address\nof Principal Executive Offices, including zip code)\n\n \n\n**Tel:\n(908) 987-3002**\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\n**N/A**\n\n(Former\nname, former address and former fiscal year, if changed since last report)\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered**\n\nCommon\nStock, par value $0.0001 per share\n \nASBP\n \nThe\nNasdaq Stock Market LLC\n\nWarrants,\neach exercisable for one share of common stock\n \nASBPW\n \nThe\nNasdaq Stock Market LLC\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\n☐\nLarge accelerated filer\n☐\nAccelerated filer\n\n☒\nNon-accelerated filer\n☒\nSmaller reporting company\n\n \n☒\nEmerging growth company\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐‌\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒\n\n \n\nAs\nof May 13, 2026 there were 1,295,234 shares of Common Stock, par value $0.0001 per share and 20,198 warrants, each exercisable for one\nshare of Common Stock issued and outstanding.\n\n \n\n \n\n** **\n\n \n\n \n\n** **\n\n**ASPIRE\nBIOPHARMA HOLDINGS, INC.**\n\n**FORM\n10-Q FOR THE QUARTER ENDED MARCH 31, 2026**\n\n**TABLE\nOF CONTENTS**\n\n \n\n \n \n**Page**\n\n[PART 1 – FINANCIAL INFORMATION](#sw_001)"}